B[ACKGROUND AND]{.smallcaps} A[IMS]{.smallcaps} {#sec1-1}
===============================================

Alpha-glucosidase inhibitors (AGIs) are widely used especially in Asian countries as a treatment option for type 2 diabetes patients with high postprandial glycaemia.\[[@ref1]\] However, data from South Asia region is very limited, therefore, we had conducted 2 international Non-Interventional Studies (NIS)\[[@ref2]\] and pooled those with old Post-Marketing Surveillances (PMS).\[[@ref3][@ref4][@ref5]\] Here report subgroup data for Asian patients from South Asia region.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

In order to examine the effectiveness of AGI in real life setting, we pooled 10 PMS/NISs from all over the world from the launch of acarbose to date, and the data were exploratory analyzed by subgroups. Data from 10 post-marketing surveillance studies (PMS) and non-interventional studies (NIS) were pooled in a single database. These studies included data from 62,905 patients from China (27.9%), Germany (18.7%), Pakistan (11.0%), Taiwan (11.0%), Poland (6.8%), Japan (4.4%), Korea (3.9%), India (3.2%), Indonesia (3.1%), and the Philippines (2.7%). Data from 11 other countries are also included as follows: Algeria, Bosnia and Herzegovina, Cambodia, Hong Kong, Malaysia, the Middle East, Morocco, Russia, Singapore, Thailand and Vietnam (all \< 2.6%). Data on postprandial plasma glucose (PPG), fasting blood glucose (FBG), glycosylated hemoglobin (HbA1c), and/or BW were collected at the baseline visit and at the post-treatment visits. The final visit ranged from 0.1 to 108.9 weeks, with a mean of 12.2 weeks and a median of 12.9 weeks. A total of 80% of patients had data for the 3-month (±4 weeks) visit, at a mean of 12.4 weeks and a median of 12.9 weeks.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

In total 62,905 patients were pooled from 21 countries and regions. Mean follow up (± SD) was 12.2 ± 4.8 weeks (range 0.1-108.9). From South Asia region (India and Pakistan, Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}), 8,738 Asian patients were enrolled.
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Mean PPG decreased from 240.0 and 261.1 mg/dl at baseline by 70.26 ± 65.10 and 82.96 ± 56.59 mg/dl at the last visit in total and South Asian populations, respectively (*n* = 53,883; *n* = 7,991, *P* \< 0.0001 for both). Mean FPG decreased from 171.6 and 176.5 mg/dl at baseline by 38.48 ± 47.83 and 49.59 ± 41.41 mg/dl at the last visit in total and South Asian populations, respectively (*n* = 56,672; *n* = 7,837, *P* \< 0.0001 for both) \[[Figure 1](#F1){ref-type="fig"}\].
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Mean HbA1c decreased from 8.4 and 8.4% at baseline by 1.11 ± 1.31% and 0.91 ± 0.93% at the last visit in total and South Asian populations, respectively (*n* = 38,843; *n* = 2,343, *P* \< 0.0001 for both) \[[Figure 1](#F1){ref-type="fig"}\].

Mean relative reduction of body weight (BW) was 1.40 ± 3.28% and 1.10 ± 3.39% at the last visit for mean baseline BW 73.6 and 74.2 kg in total and South Asian populations, respectively (*n* = 54,760; *n* = 7,718, *P* \< 0.0001 for both) \[[Figure 2](#F2){ref-type="fig"}\].
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Reductions of all glycemic parameters and BW were baseline-dependent (the higher, the more). In the heaviest baseline BW category (≥100 kg), 2.79 ± 4.03% relative reduction in BW (*n* = 3,000, *P* \< 0.0001) was observed (total population).

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

The current subanalysis of South Asia data from pooled analysis of 10 NIS/PMS shows consistent improvement in glycemic parameter as reported earlier in published studies.\[[@ref2][@ref3][@ref4][@ref5]\] Recently, IDF has released the updated guideline and recommended, AGIs as an alternative 1^st^ and 2^nd^ line and as 3^rd^ line agent alone or in combination with other oral antidiabetic agents and/or insulins.\[[@ref1]\]

In current pooled analysis, safety data was not analyzed, hence, no further discussion on the topic is possible. However, individually published studies\[[@ref2][@ref3][@ref4][@ref5]\] confirms that acarbose was very well tolerated and no major safety concerns were reported.

Consistent with RCT meta-analyses,\[[@ref6]\] post-hoc analysis of real-life data showed acarbose treatment improved glycaemic control and reduced the BW.

C[ONCLUSION]{.smallcaps} {#sec1-5}
========================

Acarbose treatment in real life setting showed significant reductions in all glycemic parameters and BW in Asian patients from South Asia region.

**Source of Support:** Nil

**Conflict of Interest:** None declared
